

Adalimumab

Section	Indications
<p>Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL</p>	<ul style="list-style-type: none"> Axial spondyloarthritis Crohn disease site Rheumatoid arthritis

Azathioprine

Section	Indications
<p>Immunomodulators for non-malignant disease Oral > Solid: 50 mg Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt) Oral > Liquid: 10 mg per mL Oral > Solid > tablet: 50 mg (scored); 25 mg</p>	<ul style="list-style-type: none"> Relapsing-remitting multiple sclerosis Failure or rejection of transplanted organs or tissues

Certolizumab pegol

Section	Indications
<p>Immunomodulators for non-malignant disease</p>	<ul style="list-style-type: none"> Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Ciclosporin

Section	Indications
<p>Immunomodulators for non-malignant disease Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection Oral > Liquid: 100 mg per mL Oral > Solid > capsule: 25 mg</p>	<ul style="list-style-type: none"> Failure or rejection of transplanted organs or tissues

Etanercept

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis
	Therapeutic equivalent to adalimumab for Crohn disease site
	Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Fingolimod

Section	Indications
Immunomodulators for non-malignant disease Oral > Solid: 0.25 mg; 0.5 mg	Relapsing-remitting multiple sclerosis

Golimumab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis
	Therapeutic equivalent to adalimumab for Crohn disease site
	Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Infliximab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis
	Therapeutic equivalent to adalimumab for Crohn disease site
	Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Methotrexate

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: pre-filled syringe in multiple strengths	Crohn disease site Psoriatic arthritis

Tacrolimus

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > IV: 5 mg per mL in 1 mL vial Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)	Failure or rejection of transplanted organs or tissues